European Union - English - EMA (European Medicines Agency)

astellas pharma europe bv - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult kidney or liver allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - follitropin beta - infertility; hypogonadism - sex hormones and modulators of the genital system, - in the female:fertavid is indicated for the treatment of female infertility in the following clinical situations:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomifene citratecontrolled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi).in the male:deficient spermatogenesis due to hypogonadotrophic hypogonadism.

European Union - English - EMA (European Medicines Agency)

teva b.v. - efavirenz - hiv infections - antivirals for systemic use - efavirenz is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (hiv-1)-infected adults, adolescents and children 3 years of age and older.efavirenz has not been adequately studied in patients with advanced hiv disease, namely in patients with cd4 counts < 50 cells/mm3, or after failure of protease inhibitor (pi)-containing regimens. although cross-resistance of efavirenz with protease inhibitors (pis) has not been documented, there are at present insufficient data on the efficacy of subsequent use of pi-based combination therapy after failure of regimens containing efavirenz.

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.

European Union - English - EMA (European Medicines Agency)

teva b.v.  - nevirapine - hiv infections - antivirals for systemic use - nevirapine teva is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv 1 infected adults, adolescents, and children of any age.most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (nrtis). the choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 3mg